Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. CSL Limited
  6. News
  7. Summary
    CSL   AU000000CSL8


Delayed Quote. Delayed Australian Stock Exchange - 01/25 12:10:14 am
258.35 AUD   -1.61%
01/06CSL : Notification regarding unquoted securities - CSL
01/04Australian shares fall from 5-month high as tech losses weigh
2021Australian shares flat as banks negate gains in mining, tech stocks
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Australia's CSL in exclusive talks for $7 billion buyout of Swiss Vifor Pharma - report

12/02/2021 | 06:49pm EST
The logo of Swiss drugmaker Vifor Pharma in Glattbrugg

(Reuters) - Australian biopharmaceutical giant CSL Ltd is in exclusive talks to buy Swiss drugmaker Vifor Pharma in a A$10 billion ($7 billion) deal, Australian media reported, sending the Swiss drugmaker's shares up by a fifth.

After discussing a potential deal since March, the companies were now in advanced talks and CSL, the world's largest maker of blood plasma treatments, was carrying out due diligence on the Swiss firm, according to reports in The Australian Financial Review and The Australian.

The reports said the deal valued the Swiss company, which makes prescription medications and is focused on treatment of kidney disease, at about A$10 billion without giving further details about the potential deal.

Both Vifor Pharma and CSL said in separate statements that they will not comment on the speculation.

Morgan Stanley analysts said in a research note that CSL may be seeking diversification because blood plasma collections - where it pays people to give blood, which it then converts to treatments - remained depressed due to COVID-19 restrictions.

"Diversification could be wise, although it could lead to near-term de-rating until any potential synergies are evident to the market," the Morgan Stanley note said.

Jefferies analysts said in a note that the potential buyout would be "a departure in terms of therapeutic area for CSL but does tie into their nascent kidney transplant franchise".

Vifor's shares closed 21% higher at the top of Swiss mid-cap index on Thursday. CSL shares were down 1% in early trading on Friday, against a slightly higher overall market.

($1 = 1.4083 Australian dollars)

(Reporting by Byron Kaye in Sydney and Shashwat Awasthi, Alexander Kloss and Sameer Manekar; Editing by Anil D'Silva and Stephen Coates)

ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
CSL LIMITED -1.61% 258.35 Delayed Quote.-9.68%
VIFOR PHARMA AG 0.59% 162.5 Delayed Quote.-0.43%
All news about CSL LIMITED
01/06CSL : Notification regarding unquoted securities - CSL
01/04Australian shares fall from 5-month high as tech losses weigh
2021Australian shares flat as banks negate gains in mining, tech stocks
2021Australian Shares Climb to Five-Day High on Boost from Healthcare Counter; Marley Spoon..
2021Healthcare, mining stocks help Australian shares notch best day in 2 weeks
2021Global biotherapeutics - CSL Behring Receives Accelerated CHMP Assessment for Etranacog..
2021Australian Shares on Three-Day Fall; Debutant XPON Technologies Jump 20%
2021CSL, energy stocks drag Australia shares lower; tech rally limits losses
2021CSL Closes $4.5 Billion Share Placement; to Open Share Purchase Plan; Shares Sink 8%
2021CSL drags Australian shares lower, tech stocks rise
More news
Analyst Recommendations on CSL LIMITED
More recommendations
Financials (USD)
Sales 2022 10 598 M - -
Net income 2022 2 222 M - -
Net Debt 2022 4 886 M - -
P/E ratio 2022 39,2x
Yield 2022 1,14%
Capitalization 89 904 M 89 330 M -
EV / Sales 2022 8,94x
EV / Sales 2023 8,10x
Nbr of Employees 25 000
Free-Float -
Duration : Period :
CSL Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CSL LIMITED
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 14
Last Close Price 187,79 $
Average target price 234,02 $
Spread / Average Target 24,6%
EPS Revisions
Managers and Directors
Paul Roger Perreault Chief Executive Officer, Executive Director & MD
Joy Carolyn Linton Chief Financial Officer
Brian Anthony McNamee Chairman
Andrew Cuthbertson Chief Scientific Officer & Executive Director
William Mezzanotte Chief Medical Officer, EVP & Head-R&D
Sector and Competitors